Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
103.7 SEK | -0.38% | +3.18% | -18.41% |
Sales 2023 | 1.21B 110M | Sales 2024 * | 1.94B 177M | Capitalization | 5.57B 509M |
---|---|---|---|---|---|
Net income 2023 | -466M -42.6M | Net income 2024 * | 85M 7.77M | EV / Sales 2023 | 5.65 x |
Net cash position 2023 | 7.14M 652K | Net cash position 2024 * | 125M 11.43M | EV / Sales 2024 * | 2.81 x |
P/E ratio 2023 |
-14.6
x | P/E ratio 2024 * |
24.5
x | Employees | 181 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 73.29% |
Latest transcript on Calliditas Therapeutics AB
1 day | -0.38% | ||
1 week | +3.18% | ||
Current month | -8.55% | ||
1 month | -9.98% | ||
3 months | -11.74% | ||
6 months | +12.35% | ||
Current year | -18.41% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 17-05-17 | |
Director of Finance/CFO | 47 | 17-07-31 | |
Chief Tech/Sci/R&D Officer | 60 | 20-07-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 74 | 23-05-29 |
Henrik Stenqvist
BRD | Director/Board Member | 57 | 21-12-31 |
Elmar Schnee
CHM | Chairman | 65 | 19-05-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 10 M€ | -3.35% | - | |
0.00% | 1 M€ | -.--% | - | |
0.00% | 29 M€ | -3.53% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 103.7 | -0.38% | 228,447 |
24-04-25 | 104.1 | +3.69% | 115,009 |
24-04-24 | 100.4 | 0.00% | 123,026 |
24-04-23 | 100.4 | +0.10% | 85,841 |
24-04-22 | 100.3 | -0.20% | 108,878 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.41% | 512M | |
+5.31% | 69.91B | |
+10.97% | 9.03B | |
-16.83% | 4.75B | |
+43.48% | 4.31B | |
+3.20% | 3.88B | |
+18.82% | 2.37B | |
-21.36% | 2.26B | |
-29.67% | 2.2B | |
+8.38% | 1.98B |
- Stock Market
- Equities
- CALTX Stock